In a recent study, it was found that Urolithin A is more potent than Doxorubicin in inhibiting Topoisomerase 2, hence, calling for its addition to the current guidelines for the treatment of certain cancers.
Daraasad dhowaan la sameeyay, waxaa la ogaaday in Urolithin A uu ka awood badan yahay Doxorubicin si looga hortago Topoisomerase 2, sidaa darteed, isagoo ku baaqaya in lagu daro tilmaamaha hadda jira ee daaweynta kansarrada qaarkood.